Integrating Public Health Concerns into Patent Legislation in Developing Countries
(2000; 140 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoTHE SOUTH CENTRE
Ver el documentoFOREWORD
Ver el documentoACKNOWLEDGEMENTS
Ver el documentoGLOSSARY*
Abrir esta carpeta y ver su contenidoI. INTRODUCTION
Abrir esta carpeta y ver su contenidoII. PATENTABLE SUBJECT MATTER
Abrir esta carpeta y ver su contenidoIII. SCOPE OF CLAIMS
Cerrar esta carpetaIV. PATENTABILITY REQUIREMENTS
Abrir esta carpeta y ver su contenidoIV.1 Novelty
Abrir esta carpeta y ver su contenidoIV.2 Inventive Step
Cerrar esta carpetaIV.3 Industrial Applicability
Ver el documentoIV.3.1 Options - Industrial Applicability
Abrir esta carpeta y ver su contenidoV. SPECIAL CASES IN PHARMACEUTICALS
Abrir esta carpeta y ver su contenidoVI. DISCLOSURE
Abrir esta carpeta y ver su contenidoVII. EXCEPTIONS TO EXCLUSIVE RIGHTS
Abrir esta carpeta y ver su contenidoVIII. EXAMINATION AND OBSERVATION PROCEDURES
Abrir esta carpeta y ver su contenidoIX. CLAIMS INTERPRETATION
Abrir esta carpeta y ver su contenidoX. COMPULSORY LICENSING
Ver el documentoXI. FINAL REMARKS
Ver el documentoREFERENCES
Ver el documentoBACK COVER
 

IV.3 Industrial Applicability

The third criterion for patentability relates to the industrial applicability of the invention. Patent law around the world aims to protect technical solutions to a given problem, not abstract knowledge. The application of this criterion to health-related inventions is particularly important vis-a-vis inventions consisting of uses of a product since uses of health-related inventions may be considered as methods of treatment of the human body, not industrially applicable, and therefore not patentable.

BOX 2
INDUSTRIAL APPLICABILITY IN COMPARATIVE LAW

Countries differ in their treatment of industrial applicability. Under US law, certain developments that do not lead to an industrial product may be patented: an invention only needs to be operable and capable of satisfying some function of benefit to humanity (“useful”)a). This usefulness concept is broader than the “industrial applicability” concept required in Europe and other countries. The U.S. rule permits the patentability of purely experimental inventions that cannot be made or used in an industry, or that do not produce a technical effectb), as illustrated by the large number of patents granted in the United States on “methods of doing business” c).

a)See, e.g., Chisum and Jacobs, 1992, p. 2-50.

b)See, e.g., Bainbridge, 1992, p. 270-272.

c)See, e.g. “The growing flood of ‘Wall Street’ patents”, in Patnews (Internet Patent New Services) of 29.9.99.

The application of the industrial applicability requirement is often complex in the chemical, pharmaceutical, and biotechnology industries, where there are particular problems relating to the acceptable degree of speculative information. Thus, in the USA mere speculation about chemical homologues would be insufficient, while in vitro testing in animal tumour models of products intended for human use may be deemed sufficientd).

d)See, e.g., Dratler, §2.03[2]

 

The TRIPs Agreement does not define the concept of industrial applicability95 and, therefore, leaves countries with considerable flexibility.

95 It allows a Member country to consider that “capable of industrial application” is synonymous with “useful”.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019